Director at Zevra Therapeutics (ZVRA) granted 30,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Zevra Therapeutics director Tamara A. Favorito received a grant of stock options for 30,000 shares of common stock on June 4, 2026. The options have an exercise price of $11.17, matching the Nasdaq closing price on the grant date, and expire on June 3, 2036. All 30,000 shares underlying the options vest 100% on the earlier of the first anniversary of the grant, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, subject to her continued board service. The grant was awarded as compensation under Zevra’s non-employee director compensation policy.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
FAVORITO TAMARA A
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 30,000 shares (Direct, null)
Footnotes (1)
- The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026. This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.
Key Figures
Stock options granted: 30,000 options
Exercise price: $11.17 per share
Underlying shares: 30,000 shares
+3 more
6 metrics
Stock options granted
30,000 options
Grant to director Tamara A. Favorito on June 4, 2026
Exercise price
$11.17 per share
Equal to Nasdaq closing price on grant date
Underlying shares
30,000 shares
Common stock underlying the stock option award
Expiration date
June 3, 2036
Option term end date
Post-transaction derivative holdings
30,000 options
Total stock options held directly after this grant
Vesting condition
100% cliff vesting
Earlier of first anniversary, pre-AGM date, or change in control
Key Terms
Stock Option (right to buy), exercise price, change in control, non-employee director compensation policy, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"The exercise price is equal to the closing price of the Issuer's common stock"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
change in control financial
"immediately prior to a change in control of the Issuer, subject in each case"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
non-employee director compensation policy financial
"pursuant to the Issuer's tenth amended and restated non-employee director compensation policy"
Nasdaq Global Select Market financial
"common stock on the Nasdaq Global Select Market on the date of grant"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
FAQ
What did Zevra Therapeutics (ZVRA) director Tamara Favorito receive in this Form 4?
Tamara Favorito received a grant of stock options for 30,000 shares of Zevra common stock. The options were awarded as compensation for her service on the board under the company’s non-employee director compensation policy.
What is the exercise price of Tamara Favorito’s new Zevra (ZVRA) stock options?
The stock options have an exercise price of $11.17 per share. This price equals the closing price of Zevra’s common stock on the Nasdaq Global Select Market on the June 4, 2026 grant date, according to the Form 4 footnotes.
When do Tamara Favorito’s Zevra (ZVRA) stock options vest?
All 30,000 option shares vest 100% on the earliest of three events: the first anniversary of the grant date, the day before the first annual stockholders meeting after the grant, or immediately before a change in control, if she continues serving on the board.
When do the Zevra (ZVRA) stock options granted to Tamara Favorito expire?
The options expire on June 3, 2036, providing a long-term window to exercise. After vesting, she may choose to exercise the options any time before this expiration date, subject to plan terms and applicable trading restrictions.
Is Tamara Favorito’s Zevra (ZVRA) Form 4 an open-market stock purchase or a compensation grant?
The Form 4 reflects a compensation grant, not an open-market purchase. The stock options were awarded under Zevra’s tenth amended and restated non-employee director compensation policy for her service on the board of directors.